Capecitabine


Entry
D01223                      Drug                                   
Name
Capecitabine (JAN/USP/INN);
Xeloda (TN)
Product
XELODA (Genentech)
  Generic
CAPECITABINE (Accord Healthcare), CAPECITABINE (American Health Packaging), CAPECITABINE (Amneal Pharmaceuticals LLC), CAPECITABINE (Areva Pharmaceuticals), CAPECITABINE 150MG (Armas Pharmaceuticals), CAPECITABINE 500MG (Armas Pharmaceuticals), CAPECITABINE (Ascend Laboratories), CAPECITABINE (Aurobindo Pharma Limited), CAPECITABINE (AvPAK), CAPECITABINE (BluePoint Laboratories), CAPECITABINE (CELLTRION USA), CAPECITABINE (Cipla USA), CAPECITABINE (Dr. Reddy's Laboratories Limited), CAPECITABINE (Golden State Medical Supply), CAPECITABINE (Golden State Medical Supply), CAPECITABINE (Hikma Pharmaceuticals USA), CAPECITABINE (Lifestar Pharma LLC), CAPECITABINE (MSN LABORATORIES PRIVATE LIMITED), CAPECITABINE (Mylan Pharmaceuticals), CAPECITABINE (NORTHSTAR RXLLC), CAPECITABINE (Novadoz Pharmaceuticals LLC), CAPECITABINE (Rising Pharmaceuticals), CAPECITABINE (Sun Pharmaceutical Industries), CAPECITABINE (Teva Pharmaceuticals USA)
Formula
C15H22FN3O6
Exact mass
359.1493
Mol weight
359.3501
Structure
Simcomp
Class
Antineoplastic
 DG02018  Antimetabolite
  DG01958  Nucleic acid derivative, antineoplastic
   DG01935  Fluoropyrimidine antineoplastic
Metabolizing enzyme substrate
 DG01642  CYP2C9 substrate
Remark
Same as: C12650
Therapeutic category: 4223
ATC code: L01BC06
Product: D01223<JP/US>
Efficacy
Antineoplastic, Antimetabolite
  Disease
Colorectal cancer [DS:H00020]
Breast cancer [DS:H00031]
Comment
Active form of prodrug: Fluorouracil [DR:D00584]
Target
TYMS [HSA:7298] [KO:K00560]
  Pathway
hsa00240  Pyrimidine metabolism
hsa00670  One carbon pool by folate
Metabolism
Enzyme: CYP2C9 [HSA:1559]
Interaction
Structure map
map07041  Antineoplastics - antimetabolic agents
Other map
map00983  Drug metabolism - other enzymes
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01B ANTIMETABOLITES
    L01BC Pyrimidine analogues
     L01BC06 Capecitabine
      D01223  Capecitabine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antimetabolites
   Capecitabine
    D01223  Capecitabine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   422  Antimetabolites
    4223  Fluorouracils
     D01223  Capecitabine (JAN/USP/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG02018  Antimetabolite
   DG01958  Nucleic acid derivative, antineoplastic
    DG01935  Fluoropyrimidine antineoplastic
     D01223  Capecitabine
 Metabolizing enzyme substrate
  DG01642  CYP2C9 substrate
   D01223  Capecitabine
Drug classes [BR:br08332]
 Antineoplastic
  DG02018  Antimetabolite
   D01223  Capecitabine
Target-based classification of drugs [BR:br08310]
 Enzymes
  Transferases (EC2)
   Methyltransferases
    TYMS
     D01223  Capecitabine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D01223
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D01223
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D01223
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and mutations affecting drug response
  D01223
Other DBs
CAS: 154361-50-9
PubChem: 7848286
ChEBI: 31348
LigandBox: D01223
NIKKAJI: J949.163E
KCF data

ATOM        25
            1   C1y C    11.2700  -21.5600
            2   C1y C    12.6700  -21.5600
            3   C1y C    13.1600  -20.2300
            4   O2x O    11.9700  -19.4600
            5   C1y C    10.8500  -20.2300
            6   C1a C     9.5200  -19.8100
            7   O1a O    10.4300  -22.7500
            8   O1a O    13.5100  -22.7500
            9   N4y N    14.4900  -19.8100
            10  C8y C    15.6800  -20.5100
            11  N5x N    16.9400  -19.8100
            12  C8y C    16.9400  -18.4100
            13  C8y C    15.7500  -17.7100
            14  C8x C    14.4900  -18.4100
            15  O5x O    15.6800  -21.9100
            16  X   F    15.7500  -16.3800
            17  N1b N    18.1300  -17.7100
            18  C7a C    19.3200  -18.4100
            19  O7a O    20.5100  -17.7100
            20  C1b C    21.7000  -18.4100
            21  C1b C    22.8900  -17.7100
            22  C1b C    24.0800  -18.4100
            23  C1b C    25.2700  -17.7100
            24  C1a C    26.4600  -18.4100
            25  O6a O    19.3200  -19.8100
BOND        26
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     1   5 1
            6     5   6 1 #Up
            7     1   7 1 #Down
            8     2   8 1 #Down
            9     3   9 1 #Up
            10    9  10 1
            11   10  11 1
            12   11  12 2
            13   12  13 1
            14   13  14 2
            15    9  14 1
            16   10  15 2
            17   13  16 1
            18   17  18 1
            19   17  12 1
            20   18  19 1
            21   19  20 1
            22   20  21 1
            23   21  22 1
            24   22  23 1
            25   23  24 1
            26   18  25 2